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Endothelium-Dependent Vasodilating Effect of Substance P During
Flow-Reducing Coronary Stenosis in the Dog
AKITO YATANI, MD, MITSUHIRO YOKOYAMA, MD, HOZUKA AKITA, MD,
HISASHI FUKUZAKI, MD
Kobe, Japan
The effects of substance P, a putative central and peripheral
neurotransmitter, on coronary vasculature and its mecha-
nisms were studied in 31 anesthetized open chest dogs.
Without coronary stenosis, intracoronary infusion of sub-
stance P (0.001 to 1 pmoIlkg per min) for 40 s increased
coronary blood flow up to 173 ± 10.7% in dose-dependent
fashion. Application of coronary stenosis created by an
inflated intraluminal microballoon that preserved active
vasomotion of the stenosed segment produced a pressure
gradient of 34 ± 2 mm Hg, a decrease in rest coronary
blood flow of 21 ± 1.6% and significant depression of the
rate of rise in left ventricular pressure (dP/dt). During
coronary stenosis, substance P increased coronary blood
flow up to 150 ± 9.4%, lowered mean distal coronary
pressure and decreased stenosis resistance in dose-
dependent fashion.
After endothelial denudation of the proximal part of the
coronary artery, the substance P·induced increments in
coronary blood flow during coronary stenosis were abol-
Substance P is an II-amino acid peptide that was first
isolated by von Euler and Gaddum (1). Extensive histochem-
ical studies (2-8) in mammals have detected a widespread
distribution of this peptide in different parts of the central
and peripheral nervous systems (2), including the heart (3,4)
and blood vessels (5-8). Substance P-like immunoreactive
nerve fibers and varicosities are located extensively in the
adventitia and the adventitia-media border of blood vessels
(5,7). Substance P, a possible neurotransmitter (9), is
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ished. In vitro measurements of isometric tension from both
intact and denuded portions of coronary arteries confirmed
a marked inhibition of substance P·induced relaxation in
the denuded segments. These results show the obligatory
role of the endothelium in substance P·induced coronary
artery dilation. Furthermore, intracoronary infusion of
substance P (1 pmoIlkg per min) from the site distal to
coronary stenosis that precluded the responsiveness of the
large coronary artery decreased coronary blood flow by 24
± 4%, lowered mean distal coronary pressure by 15 ± 1.9
mm Hg and intensified stenosis resistance by 77 ± 7.2%.
Thus, substance P exerts a direct potent dilating effect
on both large and small coronary arteries. However, be-
cause of its strict endothelium-dependency, this peptide
may play a detrimental role in the regulation of coronary
blood flow when an atherosclerotic stenotic lesion with
endothelial damage or dysfunction is present in the proxi-
mal part of the coronary artery.
(J Am Coil CardioI1990;15:1374-84)
thought to partIcIpate in cardiovascular reflexes and the
transmission of cardiac pain (6). Systemic infusion of this
peptide in animals produced a rapid decrease in blood
pressure and associated tachycardia (10). Local infusion of
the peptide in human forearm vasculature revealed that it
was a potent arteriolar vasodilator (11,12). Brum et al. (8)
found significant concentrations of substance P-like immu-
noreactivity in canine epicardial coronary arteries, and pro-
posed that it might directly affect coronary vascular tone
after its release from peripheral sensory nerve endings. The
peptide exerts potent endothelium-dependent dilatory re-
sponses in studies using isolated arterial preparations (13)
and intact canine femoral arteries (14).
These observations have raised the question as to the
possible roles of this peptide and the influences of coronary
stenosis on regulating coronary blood flow in an intact
animal. Although some investigations described the effects
of this peptide on coronary circulation in the isolated (15)
and intact (16) dog heart, none of these studies were per-
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formed under the condition of coronary stenosis or endothe-
lial dysfunction, or both, resembling human atherosclerotic
coronary lesions.
We have developed an experimental model of dynamic
coronary stenosis that preserves active vasomotion of the
stenosed segment, resembling human atherosclerotic coro-
nary lesions that contain some intact smooth muscles and
maintain stenosis vasomobility (17,18). This model has been
proved to be appropriate in investigating the effects of
vasoconstricting and vasodilating agents (19-22) and the
changes in myocardial metabolic demand (23) on the coro-
nary vasculature and the therapeutic mechanisms of cardio-
vascular drugs (20,24,25). In the present study, we evaluated
the quantitative dose-response relations of substance P to
coronary vasculature in an experimental model of coronary
stenosis and clarified the mechanisms involved in the ob-
served effects.
Methods
Experimental preparation. This project conformed to the
"Position of the American Heart Association on Research
Animal Use" adopted by the American Heart Association.
Thirty-one mongrel dogs of either gender. weighing II to
18 kg, were pretreated with subcutaneous morphine (I mg/kg
body weight), anesthetized with intravenous alpha-
chloralose (100 mg/kg) and ventilated by a mechanical res-
pirator with intermittent positive pressure, using room air
supplemented with oxygen. Blood gases and acid-base bal-
ance were maintained within normal limits (26). A catheter
was passed through the right femoral artery and advanced
into the aortic arch for aortic pressure monitoring. Another
catheter was also placed in the femoral vein for intravenous
infusion. A left thoracotomy was performed at the fifth
intercostal space, and the heart was suspended in a pericar-
dial cradle. In six dogs, a polyethylene tubing (0.6 mm outer
diameter) was advanced retrogradely through a small branch
of the circumflex coronary artery distal to the proposed
occlusion site until its tip was just distal to the stenosis for
distal coronary infusion of substance P. In the second distal
branch. another polyethylene catheter was placed to record
distal coronary pressure. A stiff catheter. 10 cm long, was
inserted into the left ventricle through the apex to record left
ventricular pressure and rate of rise of pressure (dP/dO. The
left common carotid artery was exposed, and a segment
approximately 1 cm long, of the left circumflex coronary
artery was dissected free. After administration of 5,000 U of
heparin, the circumflex coronary artery was ligated,
promptly cannulated just at its distal portion with a thin
metal cannula (2.4 mm inner diameter) and perfused contin-
uously from the carotid artery through bypass perfusion
tubing with a minimal internal diameter of 2.4 mm (Fig. I).
Heparin (2,000 U) was supplemented every 30 min.
Coronary perfusion pressure at the tip of the cannula
from Carotid Artery
::::.: Aortic Pressure
Left Ventricular Pressure
Figure 1. Experimental preparation. AO = aorta; ex = left circum-
flex coronary artery; LAD = left anterior descending coronary
artery; PA = pulmonary artery.
was measured, and it was confirmed that mean coronary
perfusion and aortic pressures were nearly identical in each
experiment. In addition, the adequacy of this perfusion
system was confirmed by preserved autoregulatory reserve
(peak reactive hyperemic response was>300% of basal flow
after a 15 s total coronary artery occlusion) in each dog.
Circumflex coronary blood flow was measured using an
extracorporeal electromagnetic flow probe (Nihon Kohden
FF-030T, inner diameter 3 mm). Pressures were measured
with a Statham P23Db transducer. Heart rate, aortic pres-
sure. mean distal coronary pressure and coronary blood flow
were continuously monitored. Each preparation was allowed
to stabilize for at least 30 min after coronary cannulation.
Production of dynamic coronary stenosis. The concept
and characteristics of dynamic coronary stenosis have been
described previously (19-25). Briefly, dynamic coronary
stenosis was produced by inflating a specially made mi-
croballoon occluder, consisting of a minute rubber balloon
attached to the tip of the polyethylene tubing. This occluder
was inserted through the side arm of the perfusion tubing and
advanced into the intact proximal portion of the circumflex
coronary artery. There was no major branch between the
cannula and the occluder. It was confirmed that the place-
ment of the occluder into the coronary artery did not affect
coronary blood flow at rest, its phasic pattern or the peak
reactive hyperemic response before its operation. The size
of the balloon was finely adjusted by expansion with saline
solution to obtain a pressure gradient across the stenosis of
approximately 30 mm Hg, and the expansion volume was
kept constant. The severity of the stenosis was evaluated by
the mean pressure gradient across the stenosis; stenosis
resistance was calculated by dividing the mean coronary
pressure gradient across the stenosis (that is, subtracting
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mean distal coronary pressure from mean aortic pressure) by
mean coronary blood flow.
Effects of intracoronary substance P administration.
Dose-response relations of intracoronary infusion of sub-
stance P (0.001, 0.01, 0.1 and 1 pmol/kg per min) were
examined in 16 dogs. The dogs were classified into two
subgroups: eight dogs without and eight dogs with coronary
stenosis. In the latter group, coronary stenosis was produced
after recordings under rest conditions. The peptide was
dissolved in a saline solution containing 0.1 % bovine serum
albumin, diluted in an appropriate concentration and infused
through the bypass tubing into the circumflex coronary
artery (proximal infusion) for 40 s at a rate of0.2 ml/min. The
response to the peptide was always apparent within this time
period. Because the hemodynamic changes in response to
this peptide were relatively transient, maximal responses of
each hemodynamic variable were observed in each pertur-
bation. In the preliminary study, it was confirmed that
this perfusion rate of substance P vehicle did not affect
coronary hemodynamic variables and that the transit time
between injection site and cannula tip was less than a
few seconds in the presence and absence of coronary steno-
sis. The sequence of varying doses of the peptide was
selected randomly. Under each condition, at least 20 min
were interposed between each perturbation to confirm the
full recovery of all hemodynamic variables to the control
state and exclude the possible development of tachyphy-
laxis.
Effects of endothelial denudation in vivo. To examine the
role of the endothelium in response to intracoronary sub-
stance P administration, endothelial denudation was per-
formed around the site where the microballoon occluder was
placed in eight dogs. After the effects of substance P (0.1 and
1pmol/kg per min) infusion for 40 s were examined without
and with coronary stenosis as control studies, endothelial
denudation was performed. A 2F Fogarty embolectomy
catheter (American Edwards Laboratories) was inserted
through the side arm of the perfusion tubing and placed in
the proximal portion of the circumflex artery. The intima of
this portion was mechanically deendothelialized by balloon
inflation and drawing of the catheter. The balloon size
of the embolectomy catheter was previously adjusted so as
not to distend the artery. The microballoon occluder
was then placed in the portion of the artery where mechan-
ical rubbing had been applied. The effects of intracoro-
nary substance P (0.1 and 1 pmol/kg per min) were again
examined in the absence and presence of partial coronary
obstruction. To exclude the possibility that endothelial dam-
age might alter the responsiveness of the vascular smooth
muscle, the responses to a 40 s infusion of nitroglycerin (1
p,g/kg per min) were also compared before and after the
procedure.
Organ chamber experiment on coronary artery segments.
At the end of the denudation experiment in vivo, coronary
arteries from six dogs were immediately isolated and cleaned
of surrounding tissue. Helical strips approximately 2 mm
wide and 20 mm long were obtained from both the endothe-
lium-denuded portion of the circumflex coronary artery and
the intact proximal portion of the left anterior descending
artery. For recording isometric tension, strips were sus-
pended in 30 ml organ baths containing buffer of the follow-
ing composition (mM): sodium chloride, 118; potassium
chloride, 4.0; calcium chloride, 1.5; magnesium sulfate, 1.2;
sodium phosphate, monobasic, 1.2; sodium bicarbonate, 25;
and glucose, 5 (27), and equilibrated at 37°C with a 95%
oxygen-5% carbon dioxide gas mixture. Final pH was ap-
proximately 7.38. An initial preload of 1.5 g was applied to
each strip. The equilibration time before the relaxation
experiment was 1.5 to 2 h. The tension of the coronary artery
at rest was approximately I g. A test contraction was
induced by adding 20 mM of potassium chloride. When
developed tension attained its peak value, the strips were
relaxed by rinsing with the buffer. They were then precon-
tracted by 2 pM of prostaglandin F2u and subsequently
relaxed by the cumulative addition of substance P (l pmol to
100 nmol). Dose-response relations were determined for
each portion of coronary artery segments.
Histologic examination. To assess the morphologic char-
acteristics of the denudation site, the vascular samples from
the intact and denuded coronary arteries were fixed in a 10%
formaldehyde solution. The specimens were stained with
hematoxylin-eosin and examined microscopically.
In some dogs. vital staining was performed to confirm the
vascular area of denudation. Evans blue dye (400 mg
dissolved in 20 ml of isotonic sodium chloride solution) was
intravenously administered at the end of the experiment.
Thirty minutes later, the dog was killed and the heart was
promptly resected. The coronary tree was flushed with the
buffer, and the circumflex coronary artery was opened
longitudinally and inspected for blue staining, which signi-
fied endothelial trauma (28).
Effects of distal substance P infusion. In six dogs, the
effects of distal coronary infusion of substance P were
compared with those of proximal infusion through the per-
fusion circuit in both stenosis-absent and stenosis-present
conditions. All hemodynamic measurements were made
continuously during rest conditions, coronary stenosis, drug
infusion and for 5 min after cessation of the infusion.
Materials. Synthetic substance P (Sigma Chemical Co.)
was dissolved in normal saline solution containing 0.1%
bovine serum albumin to give a dose of0.1 mg/ml, and stored
at -80°C before use. Nitroglycerin (Millisrol, Nihonkayaku
Co., Tokyo, Japan) was dissolved in distilled water; prosta-
glandin F2u was obtained from Sigma Chemical Co. Each
agent was prepared in an appropriate dose each time before
use.
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Table 1. Systemic Hemodynamic Effects of Substance P in Eight Dogs Without Coronary Stenosis
Mean Aortic LV Pressure (mm Hg)
HR Pressure LV dP/dt
(beats/min) (mm Hg) Systolic End-Diastolic (mm Hg/s)
0.001 pmol/kg per min
Preinjection 137 ± 8.9 107 ± 5.7 132 ± 6.2 5,1 ± 0.5 2,224 ± 137
During injection 137 ± 8.8 105 ± 5.6 130 ± 6.5 5.1±0.5 2,167 ± 142
End of injection 136 ± 9.6 106 ± 5.4 130 ± 6.0 5.1 ± 0.5 2,161 ± 137
2 min after injection 136 ± 9.2 105 ± 6.4 129 ± 7.5 5.1 ± 0.5 2,162 ± 155
0.01 pmol/kg per min
Preinjection 132 ± 10.6 107 ± 5.5 130 ± 6.9 4.9 ± 0.5 2,275 ± 110
During injection 133 ± 10.9 108 ± 5.7 131 ± 7.0 4.9 ± 0.5 2,249 ± 134
End of injection 135 ± 9.9 107 ± 5.9 129 ± 7.5 4.9 ± 0.5 2,269 ± 130
2 min after injection 133 ± 9,3 106 ± 5.8 129 ± 7.8 4.9 ± 0.5 2,248 ± 141
0.1 pmol/kg per min
Preinjection 132± 11.2 108 ± 503 130 ± 6.9 5.1 ± OJ 2328 ± 155
During injection 132 ± 11.2 107 ± 6. I 131±7,3 5.1 ± 03 2360 ± 160
End of injection 132 ± 10.5 107 ± 5.5 130 ± 6.4 5.1 ± OJ 20384 ± 148
2 min after injection 133 ± 9.2 108 ± 5.4 130 ± 603 5.1 ± OJ 2,364 ± 152
I pmol/kg per min
Preinjection 140 ± 1203 108 ± 5.6 131 ± 6,5 503 ± 0.4 2,246 ± 165
During injection 139 ± 11.8 107 ± 5.9 131 ± 6.5 503 ± 0.4 2315 ± 165
End of injection 142±11.7 103 ± 5.8 128 ± 6.8 5.0 ± 0.4 2,286 ± 182
2 min after injection 141 ± 10.8 107 ± 6,0 130 ± 6.4 4.9 ± 0.4 2,251 ± 164
Values are mean values ± SEM. HR = heart rate: dP/dt = rate of rise of pressure: LV = left ventricular.
Statistical analysis. The results of in vivo experiments
were expressed as mean values ± SEM. Data for a single
response in the same dog were analyzed by Student's t
test for paired comparison. Differences among the differ-
ent doses of each group were analyzed by analysis of
variance and Tukey's test. In in vitro experiments, the
responses to the peptide were expressed as mean values
± SEM percent relaxation of the prostaglandin F2u-in-
duced contraction, and the significance of the difference
between group means was assessed with Student's t test for
Table 2. Systemic Hemodynamic Effects of Substance P in Eight Dogs With Coronary Stenosis
Mean Aortic LV Pressure (mm Hg)
HR Pressure LV dP/dt
(beats/min) (mm Hg) Systolic End-Diastolic (mm Hgls)
0.001 pmol/kg per min
Preobstruction 137 ± 8.6 106 ± 3.6 128 ± 3.5 4.8 ± 0.4 2,137 ± J13
Preinjection 135 ± 8.1 103 ± 5.0 127 ± 503 503 ± OJ' 2,009 ± 126'
During injection 133 ± 8.8 104 ± 4.8 127 ± 503 5.4 ± OJ 2.035 ± 116
0.01 pmol/kg per min
Preobstruction 140 ± 6.9 100 ± 4.0 124 ± 4.7 4.6 ± 0.4 2,164 ± 130
Preinjection 142 ± 6.2 98 ± 5.1 122 ± 5.5 503 ± OJ' 1,998 ± 97'
During injection 143 ± 6.0 99 ± 4.8 122 ± 5.5 503 ± OJ 2,002 ± 99
0.1 pmol/kg per min
Preobstruction 140 ± 9.9 102 ± 2.8 125 ± 3.0 4.6 ± OJ 2,281 ± 132
Preinjection 145 ± 803 104 ± 1.9 126 ± 3.8 5.1 ± 0.2' 2.200 ± Ill'
During injection 144 ± 9.4 104 ± 2.5 126 ± 3.8 5.1 ± 0.2 2,253 ± 134
I pmo1/kg per min
Preobstruction 137 ± 8.5 105 ± 3.2 129 ± 3.7 4.8 ± OJ 2,273 ± 128
Preinjection 145 ± 9.1 104±3.1 128 ± 3.8 503 ± OJ' 2,140 ± 121'
During injection 145 ± 9.2 105 ± 303 130 ± 4.0 5.1 ± 0.2 2,149 ± 130
'Compared with above, p < 0.05. Values are mean values ± SEM. Abbreviations as in Table 1.
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Table 3. Coronary Hemodynamic Effects of Substance P in Dogs Without and With
Coronary Stenosis
Without Coronary Stenosis With Coronary Stenosis
(n = 8) (n = 8)
SR
CBF Mean DCP CBF Mean DCP (mm Hg/ml
(ml/min) (mm Hg) (ml/min) (mmHg) per min)
0.001 pmol/kg per min
Preobstruction 23.5 ± 2.5 100 ± 3.2
Preinjection 25A ± 2.5 102 ± 6J 18.8 ± 1.9* 70 ± 3.4* 1.9 ± OA
During injection 27.9 ± 2.7* 100 ± 6.2 20.0 ± 1.8 71 ± 3A 1.8 ± OA
0.01 pmol/kg per min
Preobstruction 23.9 ± 2.2 95 ± 3.8
Preinjection 25.1±2A 101 ± 6.5 17.9 ± 1.8* 67 ± 4.1* 1.9 ± OA
During injection 29J ± 3.0* 102 ± 6.8 20.0 ± 2.7 67 ± 3.7 1.8 ± OA
0.1 pmol/kg per min
Preobstruction 23J ± 2J 99 ± 2.9
Preinjection 25.0 ± 2.6 102 ± 6J 18.6 ± 2.0* 67 ± 3.0* 2.2 ± OJ
During injection 37.0 ± 4.5* 100 ± 7.2 22.9 ± 2.2t 62 ± 4At 1.8 ± 0.2t
I pmol/kg per min
Preobstruction 23.5 ± 2.5 102 ± 2.9
Preinjection 24.6 ± 2A 102 ± 6.0 18.5 ± 2.4* 66 ± 4.2* 2.0 ± OA
During injection 43.8 ± 7.0* 98 ± 6.7t 27.9 ± 4.5* 60 ± 4.2* 1.7 ± OAt
Compared with above: *p < 0.01. tp < 0.05. Values are mean ± SEM. CBF = coronary blood flow; DCP = distal
coronary pressure: SR = stenosis resistance.
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unpaired samples. Significance was accepted at the p value
<0.05.
Results
Effects of intracoronary substance P administration. Sys-
temic and coronary hemodynamic variables in dogs without
and with coronary stenosis are shown in Tables 1 to 3.
Without coronary stenosis. intracoronary administration of
substance P (0.001 to 1 pmol/kg per min) significantly in-
creased coronary blood flow in a dose-dependent manner.
Maximal increases in coronary blood flow were 10 ± 2.5%
(p < 0.01). 16 ± 3.8% (p < 0.01). 48 ± 11.4% (p < 0.01) and
73 ± 10.7% (p < 0.01) at the doses of 0.001, 0.01. 0.1, and 1
pmol/kg per min. respectively (Fig. 2). Systemic hemody-
namic variables did not change during the infusion of any
doses of substance P (Table I). Each dose of the peptide
produced transient but significant increases in coronary
blood flow that were observed several seconds after the start
of the infusion and began to decline during the infusion
period. The coronary effects of repeated administration of
any dose of substance P were confirmed to be reproducible
at 20 min intervals.
Application of coronary stenosis (Table 2), produced a
mean pressure gradient of 34 ± 2 mm Hg (p < 0.01) and a
decrease in coronary blood flow of 21 ± 1.6% (p < 0.01).
Left ventricular dP/dt decreased by 127 ± 21 mm Hg/s (p <
0.01). During coronary stenosis. the dose-dependent in-
creases in coronary blood flow and decreases in mean distal
coronary pressure in response to intracoronary substance P
infusion were significant at doses >0.1 pmol/kg per min (Fig.
2). Maximal increases in coronary blood flow were 8 ± 4.7%
(p = NS), 10 ± 5.3% (p = NS). 31 ± 7.2% (p < 0.01) and 50
± 9.4% (p <0.01) for each incremental dose between 0.001
and 1pmol/kg per min. and maximal decreases in mean distal
coronary pressure were 5 ± 1.8 (p < 0.05) and 7 ± 2.2 mm
Hg (p < 0.01) for the doses of 0.1 and 1pmol/kg per min (Fig.
Figure 2. Percent change in coronary blood flow (IlCBF) in re-
sponse to various doses of intracoronary substance P (SP) (0.001 to
1 pmol/kg per min) without (open bars) and with (hatched bars)
coronary stenosis. Significantly different from preinjection values:
**p < 0.01.
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3). Stenosis resistance decreased significantly by administra-
tion of the two higher doses; however, changes in left
ventricular dP/dt did not reach statistical significance.
Effects of endothelial denudation in vivo (Table 4). There
were no significant differences in basal systemic and coro-
nary variables before and 15 min after endothelial removal.
Coronary blood flow increment in response to intracoronary
Figure 3. Effects of intracoronary (i.e.) substance P (SP) (I pmol/kg
per min). A. without coronary stenosis, it can be seen that substance
P increased coronary blood flow without any changes in systemic
hemodynamic variables. B, With coronary stenosis, substance P
increased coronary blood flow, with a concomitant decrease in distal
coronary pressure. However, no significant changes in left ventric-
ular (LV) end-diastolic pressure or rate of rise of pressure (dP/dt)
were seen during the experimental period.
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LV Pressure
Mean Aortic (mmHg)
HR Pressure LV dP/dt
(beats/min) (mmHg) Systolic End-Diastolic (mm Hg/s)
Before 144 ± 15.1 103 ± 4.2 131 ± 6.0 4.5 ± 0.9 2567 ± 277
After 138 ± 14.3 105 ± 4.2 133 ± 5.5 4.6 ± 0.4 2534 ± 264
CBF
(ml/min)
24.6 ± 2.7
24.6 ± 2.9
Values are mean values ± SEM. Abbreviations as in Tables I and 3.
substance P infusion without coronary stenosis (Fig. 4, right)
was not altered significantly before and after endothelial
denudation (before: 30 ± 4.4%; after: 35 ± 5.7% for 0.1
pmol/kgpermin, and before: 50 ± 4.7%; after: 51 ± 4.8% for
1 pmol/kg per min). However, coronary blood flow incre-
ment induced by this peptide during coronary stenosis (Fig.
4, right and Fig. 5A) was almost completely abolished after
this procedure (before, 25 ± 4.4%; after, 8 ± 2.2% [p < 0.01]
for 0.1 pmol/kg per min; and before, 40 ± 3.2%; after, 10 ±
3.8% [p < 0.01] for 1pmol/kg per min). Mean distal coronary
pressure decreased further, and the decrement of stenosis
resistance was completely abolished (Fig. 5A).
Intracoronary infusion ofnitroglycerin (1 J.Lg/kg per min)
was performed in seven dogs with coronary stenosis before
and after endothelial denudation. There was no significant
difference in preinjection values of systemic and coronary
hemodynamic variables before and after the procedure.
Nitroglycerin significantly increased coronary blood flow
and mean distal coronary pressure and decreased stenosis
resistance after endothelial denudation to the same extent as
before the procedure (coronary blood flow increment: be-
fore, 35 ± 11.0%; after, 28 ± 16.0%; mean distal coronary
pressure increment: before, 13 ± 3.7 mm Hg; after, 8 ± 1.5
mm Hg; stenosis resistance decrement: before, 48 ± 3.7%;
after, 37 ± 6.7%) (Fig. 5B). No significant systemic hemo-
dynamic changes were seen with intracoronary nitroglycerin
infusion before and after the procedure.
Organ chamber experiment on coronary segments. Figure
6 shows the effects of substance P on vascular tones of
isolated coronary arteries obtained from both intact and
denuded portions of the endothelium. Dose-response curves
for substance P-elicited changes in isometric tension during
precontraction by prostaglandin F2a were compared. Sub-
stance P (0.1 to 100 nmol) induced dose-dependent relax-
ation in endothelium-intact arteries. Almost maximal relax-
ation was achieved by application of 10 nmol of the peptide
(67 ± 9.0%). However, substance P-induced relaxation of
Figure 5. Effects of intracoronary substance P (SP) (A) and nitro-
glycerin (TNG) (B) on coronary hemodynamic variables during
coronary stenosis before (open circles) and after (solid circles)
endothelial denudation. Significantly different from preinjection
values: *p < 0.05, **p < 0.01; significantly different from nondenu-
dation values: tp < 0.05. The coronary hemodynamic response to
intracoronary nitroglycerin was not significantly different before and
after endothelial denudation. CBF = coronary blood flow; DCP =
distal coronary pressure; SR = stenosis resistance.
Figure 4. Percent change in coronary blood flow (~CBF) in re-
sponse to intracoronary substance P (SP) before (open bars) and
after (hatched bars) endothelial denudation. Left, without coronary
stenosis; right, during coronary stenosis. Whereas an increase in
coronary blood flow is unchanged in the absence of coronary
stenosis after removal of the endothelium, an increase in coronary
blood flow is almost abolished in the presence of coronary stenosis
after the denudation. Vertical bars indicate standard error of the
mean. Significantly different from values before endothelial denuda-
tion: **p < 0.01.
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Figure 6. Effects of substance P(SP) on helical strips obtained from
both intact (open circles) (left anterior descending) and denuded
(solid circles) (left circumflex) portion of the coronary arteries
precontracted by prostaglandin F2a (211M). Relaxation is expressed
as a percent of the contraction to prostaglandin F2a and shown as
mean values ± standard error of the mean, indicated by vertical
lines. Substance P induced a dose-dependent relaxation in the
endothelium-intact artery, but the relaxation was almost completely
abolished in the endothelium-denuded artery. Significantly different
from values of the endothelium-denuded portion: *p < 0.05, **p <
0.01.
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the endothelium-denuded arteries was almost completely
abolished (7 ± 3.7% by 10 nmol).
Histologic examination. Light microscopic study revealed
the presence of an endothelial lining in intact coronary artery
segments (Fig. 7A). Denuded segments showed the absence
of endothelial cells, with a few adherent platelets attached to
the luminal side and preserved internal elastic lamina and
media (Fig. 7B). In addition, the denuded area in the
circumflex artery in which the vital staining was performed
was clearly tinted blue by Evans blue dye. The blue-stained
area was approximately 2cm in length and was present in the
entire circumference.
Effects of distal coronary infusion of substance P. Without
coronary stenosis, increases in coronary blood flow induced
by substance P were similar between the proximal and distal
coronary infusions. The percent increments in coronary
blood flow in response to substance P infusion were 34 ±
6.9% and 27 ± 6.7% (p = NS) at 0.1 pmol/kg per min and 74
± 16.9% and 70 ± 15.1% (p = NS) at I pmol/kg per min,
respectively. With coronary stenosis, distal infusion of sub-
stance P at 0.1 pmol/kg per min did not increase coronary
blood flow significantly in contrast with proximal infusion
(23 ± 4.4% and 3 ± 4.8% for proximal and distal infusion,
respectively), and distal infusion of the peptide at its highest
dose exhibited a substantial decrease in coronary blood flow
(50 ± 12.8% increase and 24 ± 4.0% decrease for proximal
and distal infusion, respectively, p < 0.05). This decrement
in coronary blood flow was accompanied by an accentuated
decrease in mean distal coronary pressure (8 ± 1.2 versus IS
± 1.9 mm Hg) and an intensification of stenosis resistance
Figure 7. Photomicrographs of sections of canine coronary arteries
before and after endothelial denudation. A, Transverse section of
the control coronary artery with an intact endothelial cell layer. B,
Transverse section of the denuded segment of coronary artery
showing an absent endothelial layer with normal internal elastic
lamina and media with a few adherent platelets (hematoxylin-eosin
stain; original magnification x100, reduced by 29%).
(20 ± 6.6% decrease versus 77 ± 7.2% increase, p < 0.01)
(Fig. 8).
Discussion
This study demonstrates that substance P, an amino acid
peptide, is a potent dilator in both large and small coronary
arteries and that this peptide produces a beneficial effect on
coronary vasculature during dynamic coronary stenosis. The
dilating action of this peptide on epicardial coronary arteries
is present only in the presence of intact endothelium in vivo
and in vitro.
Effects of substance P without coronary stenosis. In intact
coronary circulation, intracoronary infusion of substance P
produced dose-dependent increases in coronary blood flow
without changing systemic hemodynamic variables, indicat-
ing that it has a direct vasodilatory action on the small
coronary artery. Whether this peptide has a direct action on
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Figure 8. Effects of distal substance P (SP) infusion on coronary
hemodynamic variables during coronary stenosis as compared with
proximal substance P infusion (control). Distal infusion of the
highest dose of substance P elicited a decrease in coronary blood
flow (CBF), an augmented decline in mean distal coronary pressure
(DCP) and an intensification of stenosis resistance (SR). The data
are expressed as mean ± standard error of the mean during
preinjection (P) and infusion (I) periods. Compared with preinjec-
tion: *p < 0.05, **p < 0.01, respectively; compared with corre-
sponding values in control: tp < 0.05, ttp < 0.01. respectively.
usually complete within 10 min and readily disappears after
the washout. Perhaps such shortness of biologic activity
would account for insignificant changes in left ventricular
dP/dt during the coronary flow increment elicited by the
peptide. In this experiment, tachyphylaxis was avoided
because the repeated infusion of the same dose of the
peptide after a 20 min interval caused similar hemodynamic
responses, which is in accordance with previous human
observations (31).
Effects of substance P with coronary stenosis. The effects
of substance P were evaluated under the condition of flow-
limiting coronary stenosis. In this situation, the autoregula-
tory reserve is almost exhausted in the subendocardium,
whereas some reserve is still present in the subepicardium
(20) (although regional blood flow was not measured in this
study). Intracoronary infusion of substance P during coro-
nary stenosis increased coronary blood flow together with a
decrease in mean distal coronary pressure and stenosis
resistance. This can be explained by the preferential dilation
of the large coronary artery and the concomitant dilation of
the small coronary artery. Both endothelial denudation and
distal infusion experiments were performed to further clarify
the role of this peptide in regulating large coronary artery
tone.
After endothelial denudation of the proximal coronary
artely. the coronary blood flow increment in response to
intracoronary substance P infusion without coronary steno-
sis was not significantly altered, showing that the dilating
capacity of the small coronary artery was well preserved by
this intervention. Careful attention was paid to establishing
an inflation volume of the balloon catheter to produce only
endothelial denudation without discernible overdistension of
the artery wall and smooth muscle damage. The adequacy of
this procedure was confirmed by the response to nitroglyc-
erin, a direct vascular smooth muscle dilator, and histologic
studies and the organ chamber experiment on coronary
segments. Beneficial effects of nitroglycerin during coronary
stenosis were a result of selective dilating action of the large
coronary artery (24), and this response was similar before
and after endothelial denudation. In contrast, the coronary
blood flow increment in response to the peptide during
coronary stenosis was almost completely abolished after
endothelial denudation. These results suggest that vasodila-
tor activity of substance P depends on endothelial integrity.
Distal coronary infusion of substance P increased coro-
nary blood flow to the same extent as proximal infusion
without coronary obstruction, indicating almost the same
dilatory responsiveness of the small coronary artery. In
contrast, the deleterious response of the coronary vascula-
ture to the highest dose of this peptide during coronary
stenosis can be explained by the mechanism of passive
narrowing of the stenosed segment. Briefly, potent dilation
of the small coronary artery in response to this peptide
causes a decrease in intraluminal-distending pressure distal
P
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the heart is controversial, although the localization of sub-
stance P-like immunoreactive nerves in the atrium and
within the ventricular myocardium is well observed (3,4).
Relatively high doses of the peptide, which caused systemic
hypotension, reflex tachycardia and associated increase in
cardiac output, were used in studies (16,29-31) favoring
positive cardiotropic action of this peptide. At a concentra-
tion as low as that used in other studies (15,32-34) and in
ours, this peptide may not exert a cardiotropic action.
An increase in coronary blood flow in response to sub-
stance P infusion was rapid, transient and began to disappear
within a minute, even during continued infusion. This result
is in accordance with that in other studies (11,30) in which
the peptide was infused systemically in dogs and in humans
and showed a rapid achievement of its maximal effect.
McEwan et al. (12) demonstrated that the biologic half-time
of substance P in a human forearm blood vessel is about
15 s. Desensitization to the peptide is also demonstrated (13)
in isolated arterial preparations of various species, which is
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to the stenosis and results in a paradoxic intensification of
stenosis severity (35,36). The result also minimizes any role
of flow-dependent dilation of the large coronary artery (37) in
the increase in coronary blood flow during coronary stenosis
because the mechanism of passive narrowing easily out-
stripped the flow-dependent dilator effect during coronary
stenosis. In addition, the possibility of "coronary steal" and
diversion of myocardial blood flow from subendocardium to
subepicardium should also be considered in this situation
(38).
Role of endothelial denudation. If the endothelial denuda-
tion procedure nullifies the epicardial arterial vasodilator
response, this intervention would, theoretically, produce the
same effect on coronary vasculature as that of distal infusion
experiments. However, the increment in coronary blood
flow during coronary stenosis after the denudation was not
perfectly inhibited. The reason for this small increase in
coronary blood flow may be explained by incomplete deen-
dothelialization in situ or release of a relaxing factor from the
intact endothelial cells adjacent to the damaged site, which
was completely precluded by the distal coronary infusion of
this peptide. The contribution of released prostacyclin on
endothelium-mediated vasorelaxation could be neglected
because relaxation by substance P is not influenced by
cyclooxygenase inhibitors (39).
Thus, the responses to proximal infusion of the higher
doses of substance P during coronary stenosis can be
explained by its opposing effects on coronary vasculature
(namely, a reduction in stenosis severity due to active
dilation of the intact large coronary artery and a passive
narrowing of the stenosed segment caused by small coronary
artery dilation). Net effects of the two mechanisms are
manifest in the proximal infusion experiment, but the former
effect is completely precluded in the distal coronary infusion
experiment and is markedly attenuated in the denudation
experiment.
Clinical implications. It has been suggested (40) that
endothelial damage can playa role in the pathophysiology of
coronary vasospasm. Furthermore, the relation between
atherosclerosis and vasospasm raises the possibility that
atherosclerosis-induced endothelial damage would alter
vasoactive responsiveness to neurohumoral and pharmaco-
logic stimuli. Impairment of the endothelium-dependent re-
laxation in response to agents such as acetylcholine, sub-
stance P and bradykinin has been noted in atherosclerotic
arteries of human and animals (39,41,42). This lack of
vasodilating ability in atherosclerotic arteries appears to be
important as the cause of myocardial ischemia. The precise
mechanism whereby substance P peptidergic nerves in cor-
onary arteries are activated remains to be elucidated, as well
as the extent to which they influence coronary vasodilator
tone under normal and pathophysiologic conditions in hu-
mans.
Conclusions. We have demonstrated that substance P-
induced dilation of the canine epicardial coronary artery is
endothelium-dependent in vivo and in vitro. Substance P can
induce a direct potent dilating effect on the large and small
coronary arteries and exhibits a beneficial effect in restoring
coronary blood flow during coronary stenosis. However. in
view of its strict endothelium dependence, this peptide could
playa detrimental role in the regulation of myocardial blood
flow supplied by an atherosclerotic stenotic artery with
endothelial dysfunction or damage.
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